For Some MDS Patients, Fewer Blood Transfusions May Be Possible
- New 2026 data show that luspatercept helps far more people with lower‑risk myelodysplastic syndromes (MDS) – which are a group of bone marrow cancers – break free from regular blood transfusions.
- Data from the COMMANDS clinical trial found that 76% of patients on luspatercept went at least 12 weeks without needing a transfusion, compared with 56% on the standard treatment – epoetin alfa. Many patients on luspatercept remained transfusion‑free for years
- Experts call the results “significant” and “hope‑giving,” as luspatercept not only improves anemia more effectively than epoetin alfa but also shows early signs of better long‑term outcomes, with manageable side effects.
- Luspatercept is now a leading first‑line option for transfusion‑dependent, lower‑risk MDS, especially for patients with the SF3B1 mutation, while doctors continue to monitor for disease progression with blood tests and bone marrow biopsies.
Dr. Guillermo Garcia-Manero, Chair of the Department of Leukemia at MD Anderson Cancer Center, calls the findings significant.
Read MoreWATCH: Living with MDS
Common symptoms of MDS may include frequent infections, fatigue, shortness of breath (anemia), or easy bleeding/bruising. These symptoms occur because of the bone marrow’s inability to produce enough healthy, functional blood cells.The results come from a large clinical trial called COMMANDS, which compared luspatercept with a standard medication called epoetin alfa. The study found that significantly more patients receiving luspatercept were able to stop needing regular blood transfusions altogether.
The Benefit Lasts
The COMMANDS study revealed that among the clinical trial’s participants, 76% of patients on luspatercept went at least 12 weeks without needing a transfusion, compared with 56% on epoetin alfa.
Many patients on luspatercept remained transfusion‑free for years, including 25% for 2.5 years or more, compared with 10% on epoetin alfa.
As Dr. Garcia-Manero noted, “over a quarter of the patients are long-term responders” — with some maintaining their benefit for years.
What Fewer Transfusions Means Day to Day
Reducing transfusions can have a real impact on daily life. Regular transfusions often mean hours in an infusion center, repeat lab work, and, over time, risks like iron overload or transfusion reactions. Dr. Garcia-Manero put it plainly: “less time in those chairs, fewer complications from the transfusions,” which can make a meaningful difference in how patients feel and function day to day.
What We Know About Survival
It is still too early to know whether luspatercept helps patients live longer. Early data look encouraging, but the difference has not yet been confirmed, and longer follow-up is needed. This is common in lower-risk MDS, where the disease progresses slowly, and patients may receive several treatments over many years.
Side Effects
Both treatments were generally well tolerated. Luspatercept was associated with slightly more side effects in some patients, including increases in blood pressure, but most were manageable. Fewer patients stopped luspatercept because it stopped working, supporting its ability to provide consistent, lasting benefit.
Who May Benefit
Luspatercept is currently approved and recommended as a frontline option for patients with lower-risk MDS who are transfusion-dependent or have significant anemia. Patients with a specific genetic marker called SF3B1 tend to respond especially well, though the benefit is not limited to this group. Your doctor can help determine whether this treatment is right for you.
Navigating MDS
- How A Blood Transfusion Can Help Treat The Symptoms of MDS
- Living With Myelodysplastic Syndrome (MDS): Coping With Anemia
- Reducing Need For Blood Transfusions in Low-Risk MDS Patients and Improving Quality of Life: Learning About Reblozyl
- What’s the Standard Treatment for MDS (Myelodysplastic Syndrome)?
- Treating Anemia in MDS: Revlimid vs. Reblozyl
Some patients with MDS will have their cancer evolve into acute myelogenous leukemia (AML). Thus, your doctor needs to monitor your risk. They can monitor the risk by looking at your blood counts, the amount of cancer in the bone marrow, and any genetic abnormalities.
“For the workup of MDS, you start with a regular blood check, and you confirm that someone has low blood cells,” Dr. Jun Choi, a hematologist/oncologist at NYU Langone’s Perlmutter Cancer Center, tells SurvivorNet.
“And then, when the suspicion for MDS is high, the ultimate gold standard diagnostic test is a bone marrow biopsy. And that is because the bone marrow is where all the blood cells are made. And we want to confirm that there are abnormal cells in the bone marrow.”
A bone marrow biopsy can confirm MDS.
Questions to Ask Your Doctor
- Am I a candidate for luspatercept, and is it the right first-line choice for my type of MDS?
- What would success look like — how will we know if it’s working?
- If I respond, how long might the benefit last, and what happens if it stops working?
- Are there any clinical trials, like the ELEMENT-MDS study, that I should consider?
Learn more about SurvivorNet's rigorous medical review process.
